Literature DB >> 16616332

Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton.

Andreas Wicki1, François Lehembre, Nikolaus Wick, Brigitte Hantusch, Dontscho Kerjaschki, Gerhard Christofori.   

Abstract

The expression of podoplanin, a small mucin-like protein, is upregulated in the invasive front of a number of human carcinomas. We have investigated podoplanin function in cultured human breast cancer cells, in a mouse model of pancreatic beta cell carcinogenesis, and in human cancer biopsies. Our results indicate that podoplanin promotes tumor cell invasion in vitro and in vivo. Notably, the expression and subcellular localization of epithelial markers are unaltered, and mesenchymal markers are not induced in invasive podoplanin-expressing tumor cells. Rather, podoplanin induces collective cell migration by filopodia formation via the downregulation of the activities of small Rho family GTPases. In conclusion, podoplanin induces an alternative pathway of tumor cell invasion in the absence of epithelial-mesenchymal transition (EMT).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616332     DOI: 10.1016/j.ccr.2006.03.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  210 in total

1.  Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival.

Authors:  Haruhisa Kitano; Shun-Ichiro Kageyama; Stephen M Hewitt; Ryuji Hayashi; Yoshinori Doki; Yoshitomo Ozaki; Shozo Fujino; Mikiko Takikita; Hajime Kubo; Junya Fukuoka
Journal:  Arch Pathol Lab Med       Date:  2010-10       Impact factor: 5.534

2.  Design of active transport must be highly intricate: a possible role of myosin and Ena/VASP for G-actin transport in filopodia.

Authors:  Pavel I Zhuravlev; Bryan S Der; Garegin A Papoian
Journal:  Biophys J       Date:  2010-04-21       Impact factor: 4.033

3.  Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression.

Authors:  B O Sun; Yantian Fang; Zhenyang Li; Zongyou Chen; Jianbin Xiang
Journal:  Biomed Rep       Date:  2015-07-27

4.  Epithelial-mesenchymal transition: a new target in anticancer drug discovery.

Authors:  Fabrizio Marcucci; Giorgio Stassi; Ruggero De Maria
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

5.  Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival.

Authors:  Juan Carlos de Vicente; Tania Rodríguez Santamarta; Juan Pablo Rodrigo; Juana María García-Pedrero; Eva Allonca; Verónica Blanco-Lorenzo
Journal:  Virchows Arch       Date:  2015-03-01       Impact factor: 4.064

6.  EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression.

Authors:  Xianglan Zhang; Im-Hee Jung; Young Sun Hwang
Journal:  Tumour Biol       Date:  2015-09-19

7.  Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.

Authors:  Cheng-Hao Wang; Xiao-Dong Zhu; De-Ning Ma; Hui-Chuan Sun; Dong-Mei Gao; Ning Zhang; Cheng-Dong Qin; Yuan-Yuan Zhang; Bo-Gen Ye; Hao Cai; Wen-Kai Shi; Man-Qin Cao; Zhao-You Tang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

8.  Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes.

Authors:  Aikaterini Hatzioannou; Saba Nayar; Anastasios Gaitanis; Francesca Barone; Constantinos Anagnostopoulos; Panayotis Verginis
Journal:  Oncoimmunology       Date:  2016-07-29       Impact factor: 8.110

9.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05

10.  DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.

Authors:  Pierre Saintigny; Adel K El-Naggar; Vali Papadimitrakopoulou; Hening Ren; You-Hong Fan; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Scott M Lippman; Li Mao
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.